Providers

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

Democratic leaders assert the Emergency Medical Treatment and Labor Act (EMTALA) remains vital for emergency care, countering confusion from recent policy changes affecting abortion rights and patient safety.

A teledermatology program in Georgia helped identify patients with skin lesions that warranted in-person follow-up with a physician.

Remote care reduced readmissions and improved functional outcomes in COPD in a recent study.

Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded comparable survival outcomes in a new study, challenging treatment norms.

Explore how health equity and policy shape outcomes, revealing disparities in kidney disease, atopic dermatitis, and cancer care for vulnerable populations.

New Jersey Attorney General Matthew Platkin said the question before the court is whether First Choice Women's Resource Centers can ignore a subpoena amid a state consumer fraud investigation.

A prior settlement of $6 billion was rejected because it would have shielded the Sackler family from lawsuits even from parties who were not part of the agreement.

The late-breaking abstracts presented on the last day of the 2025 European Hematology Association (EHA) Congress show “what a vibrant clinical specialty we’re in,” according to session cochair Brian Huntly, PhD.

Adolescent and young adult (AYA) patients with hematological diseases have unique needs that require a multidisciplinary strategy to ensure their mental and sexual well-being during and beyond treatment, clinicians and patients agreed.

The potential therapy for idiopathic pulmonary fibrosis is notable because not only was the small molecule discovered by artificial intelligence, but the drug’s target itself was, too.

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

A new analysis of obesity guidelines suggests more evidence is needed to develop stronger guidelines for the transition period between childhood and adulthood.

Real-world data show no significant differences in overall survival between patients with or without cytogenetic risk factors.

The findings support the clinical benefits of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD).

Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth cohorts from the Environmental Influences on Child Health Outcomes Children’s Respiratory and Environmental Workgroup.

RGX-202 shows promising efficacy in Duchenne muscular dystrophy, improving functional outcomes and biomarker expression in early trial results.

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small cell lung cancer (ES-SCLC), a study found.

Patients who remained on treatment, especially at higher doses or on tirzepatide, were more likely to achieve clinically meaningful weight loss and improved glycemic control.

Subcutaneous mosunetuzumab shows promising efficacy and safety in high-tumor burden follicular lymphoma, paving the way for outpatient treatment options.

With a 42% reduction seen in the use of hematopoietic stem cell transplantation (HSCT) throughout the decade, researchers suggest that transplantation may be reserved for more fit patients.

About 40% of people living with HIV in an international survey did not make joint decisions regarding treatment with their provider despite reporting a high amount of trust.

A new report suggests a noninvasive means to evaluate portal hypertension in patients with BCR::ABL1-negative myeloproliferative neoplasms.